Alcohol Research Group, 6001 Shellmound St., Suite 405, Emeryville, CA 94608, USA.
Alcohol Research Group, 6001 Shellmound St., Suite 405, Emeryville, CA 94608, USA.
Drug Alcohol Depend. 2022 Feb 1;231:109242. doi: 10.1016/j.drugalcdep.2021.109242. Epub 2021 Dec 24.
Excessive drinking and opioid misuse exact a high toll on U.S. lives and differentially affect U.S. racial/ethnic groups in exposure and resultant harms. Increasing access to specialty treatment is an important policy strategy to mitigate this, particularly for lower-income and racial/ethnic minority persons who face distinctive barriers to care. We examined whether the U.S. Affordable Care Act's Medicaid expansion improved treatment utilization in the overall population and for Black, Latino, and White Americans separately.
We analyzed total and Medicaid-insured alcohol and opioid treatment admissions per 10,000 adult, state residents using 2010-2016 data from SAMHSA's Treatment Episode Data Set (N = 20 states), with difference-in-difference models accounting for state fixed effects and time-varying state demographic characteristics, treatment need, and treatment supply.
Total treatment admission rates in the overall population declined for alcohol and remained roughly flat for opioids in both expansion and non-expansion states from 2010 through 2016. By contrast, estimated Medicaid-insured alcohol and opioid treatment rates rose in expansion states and decreased in non-expansion states following Medicaid expansion in 2014. The latter results were found for alcohol treatment in the total population and in each racial/ethnic group, as well as for Black and White Americans for opioid treatment.
Medicaid expansion was associated with greater specialty treatment entry at a time when alcohol and opioid treatment rates were declining or flat. Findings underscore benefits of expanding Medicaid eligibility to increase treatment utilization for diverse racial/ethnic groups, but also suggest an emerging treatment disparity between lower-income Americans in expansion and non-expansion states.
过度饮酒和阿片类药物滥用给美国民众的生命带来了沉重的代价,并且不同程度地影响了美国的种族群体,导致了不同的暴露和后果。增加获得专业治疗的机会是减轻这一问题的重要政策策略,尤其是对于那些面临独特护理障碍的低收入和少数族裔人群。我们研究了美国平价医疗法案(Affordable Care Act)扩大医疗补助计划是否改善了总体人群以及黑人群体、拉丁裔群体和白人群体的治疗利用率。
我们使用来自 SAMHSA 的治疗阶段数据集(Treatment Episode Data Set)的 2010-2016 年数据(N=20 个州),分析了每 10000 名成年州居民中总治疗和医疗补助保险的酒精和阿片类药物治疗入院人数,采用差异中的差异模型来解释州固定效应和随时间变化的州人口特征、治疗需求和治疗供给。
在 2010 年至 2016 年期间,总体人群中总治疗入院率在酒精方面下降,在阿片类药物方面基本保持稳定,无论是在扩张州还是非扩张州。相比之下,在 2014 年医疗补助扩大之后,扩张州的 Medicaid 保险的酒精和阿片类药物治疗率上升,而非扩张州的治疗率下降。这一结果适用于总人口以及每个种族群体的酒精治疗,也适用于黑人和白人群体的阿片类药物治疗。
在酒精和阿片类药物治疗率下降或持平的情况下,医疗补助计划的扩大与更多的专业治疗进入有关。这些发现强调了扩大医疗补助资格以增加不同种族/族裔群体治疗利用率的好处,但也表明了在扩张州和非扩张州之间,低收入美国人的治疗差距正在出现。